OTC$EVFM
Evofem Biosciences Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Evofem Biosciences experienced strong growth, with net product sales more than doubling in Q4 2021 and net cash burn decreasing.
Evofem Biosciences reported a strong fourth quarter, driven by a 109% increase in net product sales compared to the previous quarter. The company also reduced its net cash burn rate and completed enrollment in a Phase 3 trial for Phexxi.
- Net product sales increased 109% to $3.6 million in the fourth quarter of 2021.
- Net cash burn rate decreased to $16.8 million in the fourth quarter of 2021.
- Enrollment completed in Phase 3 trial of Phexxi for prevention of chlamydia and gonorrhea in women.
- Secured a $50 million equity line of credit.
Headline financials
Revenue & EPS history
Evofem Biosciences · Revenue · Quarterly
$3.57M
Revenue by segment
Evofem Biosciences · $3.6M total across 1 segment · Q4 2021
- Product Sales$3.6M+2017.6%100.0%
Forward guidance
Evofem Biosciences is focused on the ongoing development of Phexxi and future growth of sales of Phexxi and the Company generally.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-4.2%
Avg return
Earnings day
-6.2%
Avg return
5 days after
-6.7%
Avg return
30 days after
29%
13 / 45 earnings
Positive
+32.4%
Q4 2023
Best reaction
-36.7%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -4.5% | +19.7% | |
| Q3 2025 | +11.1% | +11.1% | +33.3% | |
| Q2 2025 | +11.1% | +11.1% | +77.8% | |
| Q1 2025 | +12.5% | +12.5% | +25.0% | |
| Q3 2024 | -16.5% | -16.7% | -16.7% | |
| Q2 2024 | +6.4% | +11.1% | +0.0% | |
| Q1 2024 | -15.3% | -12.5% | -41.7% | |
| Q4 2023 | +32.4% | +11.1% | -5.6% | |
| Q3 2023 | +0.0% | +0.0% | +21.4% | |
| Q2 2023 | -13.3% | -13.0% | -51.1% | |
| Q1 2023 | -9.5% | -4.8% | -61.9% | |
| Q4 2024 | +0.0% | -13.6% | -13.6% | |
| Q3 2022 | -19.2% | -4.1% | -34.2% | |
| Q4 2022 | -19.2% | -4.1% | -34.2% | |
| Q2 2022 | +8.4% | -28.3% | -63.2% | |
| Q1 2022 | -18.2% | -20.7% | -51.5% | |
| Q4 2021 | -17.4% | -26.5% | -44.3% | |
| Q3 2021 | -16.3% | -31.3% | -43.3% | |
| Q2 2021 | -10.0% | -20.6% | -2.7% | |
| Q1 2021 | +16.8% | +8.1% | -14.5% | |
| Q4 2020 | -36.7% | -36.9% | -43.9% | |
| Q3 2020 | -3.7% | -10.6% | -11.8% | |
| Q2 2020 | -5.0% | -8.4% | +11.9% | |
| Q1 2020 | -2.0% | -0.4% | -35.2% | |
| Q4 2019 | -19.8% | -21.3% | +1.0% | |
| Q3 2019 | +0.8% | +5.1% | +34.9% | |
| Q2 2019 | -10.7% | -6.8% | -1.3% | |
| Q1 2019 | +31.8% | +59.6% | +49.9% | |
| Q4 2018 | -20.7% | -21.4% | -15.7% | |
| Q3 2018 | -9.8% | -12.1% | -8.8% | |
| Q2 2018 | -5.1% | -7.8% | +87.1% | |
| Q1 2018 | -11.4% | -15.6% | -46.9% | |
| Q4 2017 | -3.5% | -3.0% | -5.3% | |
| Q3 2017 | -3.2% | +2.4% | +13.7% | |
| Q2 2017 | -17.4% | -23.0% | -27.2% | |
| Q1 2017 | +2.2% | +8.6% | -0.5% | |
| Q4 2016 | -2.1% | -2.1% | +31.5% | |
| Q3 2016 | +0.9% | +0.9% | -1.7% | |
| Q2 2016 | -11.9% | -11.8% | +8.9% | |
| Q1 2016 | -6.9% | — | — | |
| Q4 2015 | +4.8% | — | — | |
| Q3 2015 | -6.4% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | +6.5% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro